Wockhardt to exit residual US generics business for “commercial reasons”
[ad_1] Drugmaker Wockhardt has decided to exit its remaining generics business in the US, for commercial reasons. Over two years ago, the Mumbai-based drugmaker had
Day 1 after diabetes drug Empagliflozin goes off patent, generics go to town with it
[ad_1] Drugmakers have begun to roll-out their generic versions of diabetes drug Empagliflozin – on day one after the innovative drug from Boehringer Ingelheim (BI)
